Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 147

Results For "STI"

6887 News Found

Wanbury unveils API facility in Tanuku, targets Rs. 100 crore revenue
News | January 30, 2026

Wanbury unveils API facility in Tanuku, targets Rs. 100 crore revenue

The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules


Shilpa Medicare & mAbTree Biologics win FDA nod for rare blood cancer therapy
Drug Approval | January 30, 2026

Shilpa Medicare & mAbTree Biologics win FDA nod for rare blood cancer therapy

The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options


Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%
News | January 30, 2026

Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%

The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year


Vetter to invest €480 million in major German manufacturing expansion, eyes 2,000 jobs
News | January 30, 2026

Vetter to invest €480 million in major German manufacturing expansion, eyes 2,000 jobs

The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024


Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience
News | January 30, 2026

Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience

The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio


Lonza posts CHF 6.5 billion in 2025 sales, marks strong profit growth
News | January 30, 2026

Lonza posts CHF 6.5 billion in 2025 sales, marks strong profit growth

Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model


Venus Remedies bags second PLI disbursement for FY25, nears full-year incentive
News | January 29, 2026

Venus Remedies bags second PLI disbursement for FY25, nears full-year incentive

The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities


Lubrizol showcases India manufacturing expansion at WHX Dubai
News | January 29, 2026

Lubrizol showcases India manufacturing expansion at WHX Dubai

The Chennai facility will manufacture high-quality medical tubing for neurovascular and cardiovascular applications, including balloon catheters and other minimally invasive devices